Get the Stockscreener App
34.14
4.63%
1.51
After Hours:
34.27
0.13
+0.38%
Apellis Pharmaceuticals Inc stock is traded at $34.14, with a volume of 2.04M.
It is up +4.63% in the last 24 hours and up +27.96% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$32.63
Open:
$33.09
24h Volume:
2.04M
Relative Volume:
0.71
Market Cap:
$4.18B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-6.5029
EPS:
-5.25
Net Cash Flow:
$-205.58M
1W Performance:
+24.19%
1M Performance:
+27.96%
6M Performance:
-15.93%
1Y Performance:
-29.30%
1-Day Range:
$32.77
$34.40
1-Week Range:
$26.62
$34.40
52-Week Range:
$24.34
$73.80
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
34.14 | 4.18B | 715.22M | -250.10M | -205.58M | -5.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - The Manila Times
Apellis Pharmaceuticals to Present at Evercore ISI and Citi Healthcare Conferences | APLS Stock News - StockTitan
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewswire Inc.
Shareholders Can't Ignore US$6.6m Of Sales By Apellis Pharmaceuticals Insiders - Simply Wall St
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock Position Decreased by Algert Global LLC - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Apellis started at equal-weight at Morgan Stanley on geographic atrophy market - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Up 8.8%Should You Buy? - MarketBeat
Landscape Capital Management L.L.C. Invests $776,000 in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Deep Track Capital, LP Reduces Stake in Apellis Pharmaceuticals Inc - GuruFocus.com
Deep Track Capital, LP Increases Stake in Apellis Pharmaceuticals Inc. - GuruFocus.com
Jennison Associates LLC Lowers Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Morgan Stanley Initiates Coverage of Apellis Pharmaceuticals (APLS) with Equal-Weight Recommendation - MSN
How to Take Advantage of moves in (APLS) - Stock Traders Daily
Morgan Stanley Begins Coverage on Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts - Benzinga
Apellis Pharmaceuticals (FRA:1JK) Degree of Operating Lever - GuruFocus.com
Victory Capital Management Inc. Sells 49,960 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y - MSN
Apellis Pharmaceuticals shares surge following Astellas Pharma’s FDA setback - Investing.com India
Apellis Pharmaceuticals shares surge following Astellas Pharma’s FDA setback By Investing.com - Investing.com Canada
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap UpTime to Buy? - MarketBeat
Apellis reiterates neutral rating, steady stock target on FDA decision - Investing.com
Apellis reiterates neutral rating, steady stock target on FDA decision By Investing.com - Investing.com UK
GSA Capital Partners LLP Purchases New Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
T. Rowe Price Investment Management Reduces Stake in Apellis Pha - GuruFocus.com
Apellis Pharmaceuticals to Present at Jefferies London Healthcare Conference 2024 | APLS Stock News - StockTitan
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference - The Manila Times
(APLS) Trading Signals - Stock Traders Daily
Fiera Capital Corp Lowers Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Wellington Management Group LLP Reduces Stake in Apellis Pharmac - GuruFocus.com
HC Wainwright Has Negative Outlook of APLS FY2024 Earnings - MarketBeat
William Blair Issues Pessimistic Forecast for APLS Earnings - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript - MSN
Robert W. Baird Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Wedbush Cuts Earnings Estimates for Apellis Pharmaceuticals - MarketBeat
Earnings call: Apellis Pharmaceuticals Q3 2024 results show promise By Investing.com - Investing.com Nigeria
Earnings call: Apellis Pharmaceuticals Q3 2024 results show promise - Investing.com
Wells Fargo & Company Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $30.00 - MarketBeat
Old West Investment Management LLC Purchases Shares of 102,403 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Oppenheimer Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $40.00 - MarketBeat
Needham & Company LLC Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $60.00 - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $57.00 by Analysts at HC Wainwright - MarketBeat
Bank of America Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $47.00 - MarketBeat
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates - MSN
Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlig - GuruFocus.com
Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance
Apellis Pharmaceuticals (APLS) Stock Moves After Q3 Results - GuruFocus.com
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results - citybiz
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday - MSN
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales - MSN
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Apellis Pharmaceuticals Inc Stock (APLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dunlop A. Sinclair | Director |
Sep 16 '24 |
Sale |
36.23 |
37,000 |
1,340,597 |
100,000 |
| Chopas James George | VP/Chief Accounting Officer |
Sep 16 '24 |
Sale |
36.21 |
192 |
6,952 |
38,141 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):